Allogeneic iNKT Cell Therapy for Hyperinflammatory ARDS

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Effective treatments for acute respiratory distress syndrome (ARDS) and its associated complications, such as multisystem organ failure and concomitant infections, remain elusive, particularly in severe cases like those caused by viral infections like COVID-19, with high mortality rates and complications from interventions like ECMO.

Innovation Solution

Administration of unmodified, allogeneic invariant natural killer T (iNKT) cells to patients with ARDS, which modulate the immune response, reduce inflammation, and prevent secondary infections, promoting an anti-inflammatory state without inducing cytokine release syndrome.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments for ARDS are used, then current standard care is provided, but mortality rate remains high and multisystem organ failure occurs

Engineering Contradiction:

Improvesurvival rateVSAvoidmortality rate

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces invariant natural killer T (iNKT) cells as an intermediary biological agent that mediates between the viral infection and the host immune system. These cells modulate the immune response by reducing excessive inflammation and preventing organ failure, thereby improving survival rates without causing harmful side effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the immunological parameters of the host by administering iNKT cells that alter cytokine production and immune cell activation. This shifts the immune response from a harmful hyperinflammatory state to a balanced anti-inflammatory state, reducing mortality and preventing multisystem organ failure.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If aggressive respiratory support interventions are used, then respiratory failure is treated, but complications such as ECMO-related issues and neurotoxicity occur

Engineering Contradiction:

Improverespiratory support effectivenessVSAvoidECMO complications and neurotoxicity

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful hyperinflammatory response into a beneficial anti-inflammatory state through iNKT cell administration. By transforming the immune response profile, the treatment reduces the need for aggressive ECMO support and minimizes associated complications and neurotoxicity while maintaining respiratory support effectiveness.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If viral infection is treated with standard therapies, then infection is addressed, but secondary bacterial and fungal infections occur

Engineering Contradiction:

Improveviral infection treatmentVSAvoidsecondary infections

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by administering iNKT cells before secondary infections can develop. These cells preemptively modulate the immune response and prevent the conditions that lead to secondary bacterial and fungal infections, thereby improving treatment reliability without causing harmful complications.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20250339468A1Invariant natural killer t cells for treating acute respiratory distress syndrome (ARDS)

Publication Date: 2025.11.06 MINK THERAPEUTICS INC

AI summary

The present disclosure, at least in part, relates to compositions comprising invariant natural kill T (iNKT) cells (e.g., unmodified, allogeneic iNKT cells), and methods of using the compositions comprising the iNKT cells for treating a disease, or a symptom or complication of a disease (e.g., viral infection, acute respiratory distress syndrome (ARDS) secondary to a primary disease (e.g., viral infection) and/or its associated organ failure).